Overview

Location [1]
8p11.23
Pathways
Receptor tyrosine kinase/growth factor signaling, Kinase fusions
Protein [2]
Fibroblast growth factor receptor 1
Synonyms [1]
N-SAM, FGFR-1, FGFBR, HRTFDS, CEK, HH2, HBGFR, FLG, BFGFR, OGD, ECCL, FLT2, CD331, bFGF-R-1, KAL2, FLT-2

FGFR1 (fibroblast growth factor receptor type 1) encodes the fibroblast growth factor receptor type 1 protein, a receptor tyrosine kinase. FGFR1 and other FGFR TKs play crucial roles in development and have been shown in cancers to be deregulated by amplification, point mutation, or translocation (PMID: 20094046).  Amplification or activation of FGFR1 has been reported in many cancers, including oral squamous cell carcinoma (PMID: 16807070), breast cancer (PMID: 20179196), esophageal squamous cell carcinoma (PMID: 12147242), ovarian cancer (PMID: 17699850), bladder cancer (PMID: 11389083), prostate cancer (PMID: 14614009), and lung cancer, predominantly in the squamous subtype (PMID: 21666749; PMID: 17982442; PMID: 21160078).

FGFR1 is altered in 3.27% of all cancers with breast carcinoma, non-small cell lung carcinoma, colorectal adenocarcinoma, malignant glioma, and ovarian neoplasm having the greatest prevalence of alterations [3].

FGFR1 GENIE Cases - Top Diseases

The most common alterations in FGFR1 are FGFR1 Amplification (2.25%), FGFR1 Mutation (1.63%), FGFR1 Loss (0.29%), FGFR1 N546K (0.12%), and FGFR1 D127Mfs*25 (0.10%) [3].

FGFR1 GENIE Cases - Top Alterations

Significance of FGFR1 in Diseases

Malignant Solid Tumor +

Urothelial Carcinoma +

Non-Small Cell Lung Carcinoma +

Multiple Myeloma +

Breast Carcinoma +

Squamous Cell Lung Carcinoma +

Cancer +

Gastric Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Esophageal Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Non-Hodgkin Lymphoma +

Glioma +

Transitional Cell Carcinoma +

Anaplastic Oligodendroglioma +

Nasal Cavity And Paranasal Sinus Carcinoma +

Small Cell Lung Carcinoma +

Malignant Salivary Gland Neoplasm +

Urethral Urothelial Carcinoma +

Infiltrating Renal Pelvis And Ureter Urothelial Carcinoma +

Glioblastoma +

Bladder Carcinoma +

Bladder Urothelial Carcinoma +

Extrahepatic Cholangiocarcinoma +

B-Cell Non-Hodgkin Lymphoma +

Endometrial Carcinoma +

Anaplastic Astrocytoma +

Lymphoma +

Pancreatic Carcinoma +

Gastrointestinal Stromal Tumor +

Intrahepatic Cholangiocarcinoma +

Cholangiocarcinoma +

B-Cell Acute Lymphoblastic Leukemia +

Diffuse Intrinsic Pontine Glioma +

Hematopoietic And Lymphoid Cell Neoplasm +

Hepatobiliary Neoplasm +

Histiocytic And Dendritic Cell Neoplasm +

Lip And Oral Cavity Carcinoma +

Malignant Laryngeal Neoplasm +

Myeloproliferative Neoplasm +

Nasopharyngeal Carcinoma +

Oropharyngeal Carcinoma +

Renal Pelvis Urothelial Carcinoma +

Ureter Urothelial Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.